Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Business Wire•24/09/2026•08:30 ET
0
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Oral presentation of the results from the RAMP 201J study of avutometinib plus defactinib in recurrent LGSOC in Japanese patients
Get started
Create a free account to read the full story and Whiz Insights.